- Starts
- 21 OCT 2026
- Ends
- 24 OCT 2026
- Link
- https://www.idweek.org/
IDWeek 2026
You may also be interested in
-
Centauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infections
Read more: Centauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infectionsCentauri today announced that the Company’s lead clinical candidate in the ABX-01 programme, CTX-187, has…
-
Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate
Read more: Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidateCentauri today announced it has secured £6M from AMR Action Fund, extending the Company’s Series…
-
Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials
Read more: Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trialsCentauri announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1M…
